News 13.10.21

Themajaar #100yearspharmafuture voor een eeuw medicijnen maken in Oss

Honderd jaar geleden is in Oss de basis gelegd voor de ontwikkeling van geneesmiddelen. Oss stond in die tijd aan de wieg van de farma-sector in Nederland, met baanbrekende ontdekkingen als insuline en de anticonceptiepil. Bedrijven zijn door het gezamenlijk verleden sterk verbonden.

Read more
News 08.10.21

Mercurna has reached its scientific and IP milestones of the RedMedtech Discovery Fund II (RMDFII)

We are pleased to share that Mercurna has reached its scientific and IP milestones of the RedMedtech Discovery Fund II (RMDFII) by providing exciting data (in vitro and in vivo) on mCura1, Mercurna’s lead formulation for chronic kidney disease.

Read more
News 29.09.21

Third ADC with Synaffix’s Technology Enters Clinical Development

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that its partner Shanghai Miracogen has commenced a Phase I trial in the US with MRG004A, an ADC designed to treat solid tumors. This is the 3rd ADC built with GlycoConnect™ ADC technology to enter the clinic.

Read more
News 29.09.21

NTRC Precision Medicine Services is now Oncolines

As an independent company, Oncolines will now be singularly focused on offering the best precision medicine services in oncology and cancer immunotherapy for our clients.

Read more
News 28.09.21

Osteo-Pharma Announces Strategic Research Collaboration Focused on Accelerating Fracture Healing in Osteoporotic patients

Osteo-Pharma, a Dutch Life Sciences company committed to developing novel medical devices and pharmaceutical products to improve local bone healing, today announced a strategic research collaboration with The Chinese University of Hong Kong (“CUHK”) to advance OsteoActivator coated membranes into various fracture healing models complementary to Osteo-Pharma’s current dental OsteoActivator membrane. This collaboration provides Osteo-Pharma with the potential to expand its development portfolio into the orthopedic arena and to have an impact on the life of osteoporotic individuals experiencing complex and difficult to heal fractures.

Read more
News 22.09.21

Pivot Park: a unique ecosystem

Pivot Park is the hotspot for pharmaceutical innovation in Brabant. It is also one of BOM's key partners in supporting start-ups developing new drugs and vaccines. In this video Brigitte Drees (Pivot Park), Helmuth van Es (Citryll) and Alexander Willemse (BioConnection B.V.) talk about a unique ecosystem at Pivot Park in Oss, where 60 companies are now located.

Read more
News 08.09.21

ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation

IMMUNOPRECISE ANTIBODIES LTD., a leader in full-service, therapeutic antibody discovery and development, announced today that its site in Oss, the Netherlands, which is part of the Company’s subsidiary, IPA Europe, has been granted a three-year approval for the “Crédit d’Impôt Recherche” (CIR) from the French Ministry of Higher Education and Research.

Read more
News 02.09.21

Ardena has acquired Idifarma, a leading Contract Manufacturer of niche and highly potent generic and innovative drugs.

Ardena has acquired Idifarma, a leading Contract Manufacturer of niche and highly potent generic and innovative drugs. The acquisition from SUANFARMA delivers expansion across Southern Europe and supports Ardena’s strategy to become a leading global CDMO, offering integrated solutions across the full pharma development lifecycle.

Read more
News 31.08.21

Eerste studenten lectoraat Drug Discovery in september op Pivot Park

Het lectoraat Drug Discovery van de Academie Toegepaste Biowetenschappen en Chemie in Nijmegen start in september met zijn eerste studenten op het lab op Pivot Park. Het lectoraat maakt deel uit van de HAN University of Applied Sciences. We zitten in de kelder van het RE-gebouw (0201), een lab waar we zowel biologische als chemische onderwerpen kunnen adresseren en waar ongeveer 10 tot 15 studenten tegelijk kunnen werken.

Read more